1132817-67-4

Basic information

• Product Name: 3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,4-diazaspiro[4.4]non-3-en-2-one
• Synonyms: 3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,4-diazaspiro[4.4]non-3-en-2-one
• CAS NO: 1132817-67-4
• Molecular Weight: 294.356
• Mol File: 1132817-67-4.mol

Chemical Properties

• CAS DataBase Reference: 3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,4-diazaspiro[4.4]non-3-en-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,4-diazaspiro[4.4]non-3-en-2-one(1132817-67-4)
• EPA Substance Registry System: 3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,4-diazaspiro[4.4]non-3-en-2-one(1132817-67-4)

Safety Data

• Hazardous Substances Data: 1132817-67-4(Hazardous Substances Data)

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 104-88-1 4-chlorobenzaldehyde 
• 822-36-6 4-methyl-1H-imidazole 
• 950589-52-3 3-(4-chlorophenyl)-1,4-diazaspiro[4.4]nonan-2-one 
• 950651-29-3 3-(4-bromophenyl)-1,4-diazaspiro[4.4]nonan-2-one 
• 167024-66-0 2-amino-2-(4-bromophenyl)acetonitrile 

Downstream Products

• 1132817-48-1 N-(3-chlorophenyl)-2-{3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}acetamide 
• 1132817-41-4 N-(3,5-difluorophenyl)-2-{3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}acetamide formate 
• 1132817-32-3 2-{3-[4-(5-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide 
• 1132817-33-4 2-{3-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-1,4-diazaspiro[4.4]non-3-en-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide 

Relevant articles and documents

Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles: Application to the synthesis of nilotinib

The completely N1-selective Pd-catalyzed arylation of unsymmetric imidazoles with aryl halides and triflates is described. This study showed that imidazoles have a strong inhibitory effect on the in situ formation of the catalytically active Pd(0)-ligand complex. The efficacy of the N-arylation reaction was improved drastically by the use of a preactivated solution of Pd2(dba)3 and L1. From these findings, it is clear that while imidazoles can prevent binding of L1 to Pd, once the ligand is bound to the metal, these heterocycles do not displace it. The utility of the present catalytic system was demonstrated by the regioselective synthesis of the clinically important tyrosine kinase inhibitor nilotinib.

Me3(OMe)tBuXPhos: A surrogate ligand for Me4tBuXPhos in palladium-catalyzed C-N and C-O bond-forming reactions

A new biarylphosphine ligand, Me3(OMe)tBuXPhos (L3), was designed as a surrogate for Me4tBuXPhos (L1). The Me 3(OMe)tBuXPhos could be prepared in a chromatography-free manner from inexpensive and readily available 2,3,6-trimethylphenol. Comparative studies demonstrated that a catalyst based on Me3(OMe)tBuXPhos displayed the same reactivity as a catalyst based on Me4tBuXPhos for Pd-catalyzed C-N and C-O bond-forming processes.

An efficient and scalable synthesis of the spirocyclic glycine transporter inhibitor GSK2137305

An efficient and scalable synthesis of a glycine transporter inhibitor is presented. The key steps in the synthetic sequence are the formation of a spirocyclic imidazolidinone from an -amino nitrile and a cyclic ketone and an arylation of 4-methyl imidazo

SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER

Compounds of formula (I) and salts thereof are provided: formula (I), wherein the groups are as defined in the specification. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.